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ICD 10 CODE L59.8
Other

Specified Disorders of the
Skin and Subcutaneous Tissue
Related to Radiation

ICD 10 Code M27.2
Inflammatory Conditions of the Jaws

What is Dead (necrosis) is Dead

Osteoradionecrosis Coexists with Adjacent Soft Tissue Injury

SEEING IS BELIEVING

TODAY’S TALK OUTLINE

•

A brief introduction of the speaker’s personal medical career with relevance to title of talk

•

Review of HBOT timeline

•

Review of HBOT as treatment for radiation injury to bone and soft tissue

•

Brief review of brain tumor status and cancer
In general

•

Detailed presentation of recent experience with HBOT as treatment for late effects of radiation therapy on brain

•

Implications for potential treatment of other and more common conditions based on brain tumor experience

•

Thoughts on approaches to off-label use of HBOT in general and for conditions similar in pathophysiology to radiation
injury to brain

•

Summation and recommendations
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Glioblastoma

DRS. GIULIO D’ANGIO AND AUDREY EVANS

First Demonstration of Cancer Cured by
Combination Chemotherapy
DeVita et al, 1986

`

“Cure is not enough, we must limit (or correct) the damage”

……..Giulio D’Angio

DR. JUDAH FOLKMAN
ANGIOGENESIS PATRIARCH

A Timeline of Hyperbaric Oxygen Medicine

1878 – Subjects of experiments by Paul Bert experience grand mal seizures while exposed to oxygen under pressure; first demonstration of oxygen
toxicity.
1879 – French surgeon J.A. Fontaine builds mobile pressurized operating room.
1955 – J Churchill Davidson uses high oxygen concentration in pressurized chamber to treat injury from radiation therapy. Ite Boerema uses
pressurized oxygen to protect patients during cardiac surgery.
1970s – With invention of cardiopulmonary bypass, HBOT loses momentum; most uses not supported by scientific data
1975 – Undersea and Hyperbaric Medical Society
convenes to write Hyperbaric Oxygen Therapy

1977 – Committee on Hyperbaric Oxygenation recognizes four categories of diseases treatable with HBOT, ranging from those with strong
supportive data to those without
1985 – Marx publishes first randomized prospective clinical trial demonstrating efficacy of HBOT for prevention of osteoradionecrosis
2012 – Feldmeier et al updates and confirms Marx’s results

2018 – There are 15 approved uses for HBOT including treatment of soft tissue late radiation injury as well as complications of osteoradionecrosis;
there are at least 2000 HBO facilities in USA (500 UHMS Accredited) vs. 37 in 1976.

Current Status of Neuro-Oncology and Cancer in General
Facts:
1. Primary brain tumors: About 50,000 per year in USA (15,000 grade IV, 15,000 grades II and III, 15,000 benign)
2. Metastatic brain tumors (mostly associated with breast cancer, melanoma, renal cancer, and lymphoma) 100,000 per year
3. Most of the above receive radiation therapy
4. Survival is about 2 years for grade IV, 5-10 years for grade III, and at least 20 years for grades I and II
5. Survival for metastatic cancer much lower, but dramatically improving, especially for melanoma
6. This translates to at least 20,000 brain tumor patients per year at risk for late effects of RT
7. It is estimated that there are >15,000,000 cancer survivors now in USA and increasing
8. 600,000 new cancer diagnoses per year of whom 50% will receive radiation therapy

HBO as Treatment for Radiation Injury
to Bone and Soft Tissue

Prevention of osteoradionecrosis: a
randomized prospective clinical trial of
hyperbaric oxygen versus penicillin
Marx RE, Johnson RP, Kline SN
J Am Dent Assoc 1985
Healing of tooth extractions with HBO 5.4% vs 29.9% without (p=.005)

Hyperbaric oxygen therapy and delayed
radiation injuries (soft tissue and bony necrosis):
2012 update.

Feldmeier JJ
Undersea Hyperb Med, 2012
Confirms previous paper showing benefit
Refutes risk of increasing risk of recurrent malignancy

Outcomes of Radiation Injuries
Using Hyperbaric Oxygen Therapy:
An Observational Cohort Study

Neizgoda JA, Serena TE, Carter MJ
Adv Skin Wound Care 2016

Summary of Findings:

1. Data obtained and analyzed on 2538 patients who were treated with HBOT for late
effects of radiation therapy

2. Informal survey (UHMS) finds that approximately 50% of patients treated with HBOT had
diagnosis of radiation injury
3. Only randomized clinical trials or cohort studies analyzed

4. Analysis supports use of HBOT as adjunctive treatment of radiation injuries

TYPES OF INJURY
Osteoradionecrosis
Dermal soft tissue injury
Cystitis
Proctitis
Laryngeal radionecrosis
Cerebral damage
Vaginosis
Colitis
Esophagitis
Enteritis

(%)
33.4
27.5
18.6
9.2
4.8
1.9
1.7
1.4
.9
.6

SUCCESSFUL USE OF HBOT TO TREAT RADIATION
ISCHEMIC BRAIN INJURY IN BRAIN TUMOR
SURVIVORS

EDWARD ARENSON, WALTER VERNON, STEVEN SNIVELY

Background and Rationale

Use of hyperbaric oxygen therapy (HBOT) for radiation injury to bone and soft tissues is an
approved therapy.

Its use for the amelioration, however, of soft tissue brain injury from radiation therapy is
uncommon and not strongly supported in the medical literature.
Since it is believed and supported through MRI imaging that radiation injury to brain is
largely a result of small vessel vasculopathy, we treated 27 irradiated and symptomatic
brain tumor survivors with HBOT in the hopes of inducing neo-angiogenesis

RATIONALE FOR USE OF HBOT TO TREAT LATE
RADIATION INJURY TO BRAIN

As opposed to non-radiation-induced soft tissue injury, in which there
is a sharp distinction between injured and healthy tissue, radiated
tissue has an an indistinct boundary and inadequate oxygen gradient
to induce neo-angiogenesis. HBOT amplifies the gradient 7-10 fold
(2.4ATM) which induces robust neo-angiogenesis.

Knighton DR et al, Surgery, 1981

Superior Tissue Delivery Of Dissolved vs. Hemoglobin-Bound Oxygen

Materials and Methods

Initially, we treated patients at 2.0 ATM and used 30-40 treatments. These were
predominantly patients who had their radiation therapy more than 100 months before HBOT.
We saw no unexpected adverse effects, so we increased the pressure on the remaining
patients to 2.4 ATM in order to maximize efficacy while avoiding air breaks and also
extended treatment to at least 60 dives. Again, no unusual adverse effects were noted.
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Percent < 60 treatments
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RESPONSE vs. MEDIAN AGE (YEARS)
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40

NON-RESPONDERS

62

CASE HISTORY

55yo woman treated at age 12 for childhood leukemia with
prophylactic whole brain radiation therapy. One of first patients to be
cured. Recent rapid loss of peripheral visual fields in a pattern
consistent with late optic radiation vasculopathy. No other cause
identified. Visual field results after 48 of 60 planned treatments of HBO.

RT EYE
Before HBO

After HBO

LEFT EYE
Before HBO

After HBO

Cerebrovascular Disease with Atrophy

Cerebrovascular Disease with
Atrophy

CONCLUSIONS

1.
HBOT was safe in irradiated brain tumor survivors at 2.4 ATM without air
breaks and was not observed to increase risk or frequency of seizures.

2. No patient who received HBOT in this clinical setting experienced
worsening of neurological function or MRI evidence of progressive
vasculopathy.
3. Sixty-eight per cent of treated patients experienced either combined
clinical and radiographic benefit (n=16) or only radiographic improvement
(n=1).

4. All of the 32% of patients who did not improve after HBOT, save two relatively
elderly patients, were treated more than 100 months post RT. This observation
is highly statistically significant. If we exclude those patients whose HBOT was
initiated more than 100 months after RT, the response rate was 89%. (This level
of response is similar to levels achieved in other anatomical sites in recent
review by Niezgoda et al)
5. A broad spectrum of clinical symptoms were observed to improve in selected
patients including fatigue, memory, multi-tasking, navigation, executive
function, somnolence, motor dysfunction and seizure control. This was
demonstrated both by clinical observation and repeat neuro-cognitive testing.

HBOT in this unique group of patients is surprisingly effective
and deserves more study to better define its optimum
application. It is notable that areas of brain remote from the
field of radiation demonstrated improved vascularity after
HBOT which suggests that some clinical improvement might
be attributable to amelioration of vascular disease
unrelated to RT.

Ischemic Radiation Brain Injury may be
the Only Chronic Brain Condition for which
there is a Treatment (HBOT) which Provides
Demonstrable and Durable Improvement
Rather than Temporary Control

LEVELS OF CLINICAL EVIDENCE
HIERARCHY
•

Meta-Analysis of multiple randomized clinical trials,
preferably double-blinded

•

Single randomized clinical trial, preferably blinded

•

Cohort Studies

•

Retrospective reviews

•

Anecdotes of limited numbers of patients

•

Multiple patients serving as their own controls (usually
not listed as valid)

A Few Conditions Similar in Pathophysiology to Radiation Injury of Brain
(in which there are symptomatic areas of ischemia without necrosis or loss of
neurons or nerves)

•

Any form of vascular dementia, i.e. hypertension, hyperlipidemia, diabetic,
vasculitis, Alzheimer’s disease, (60% of diabetics develop dementia)

•

Diabetic Polyneuropathy

•

Diabetic Retinopathy

•

Diabetic Nephropathy

•

Avascular necrosis of hip, knee, etc.

•

Small vessel peripheral vascular disease

•

Lyme disease

Hyperbaric Oxygen Therapy Has a
Bright Future BUT……….
Indiscriminate Use Without Strong Supporting
Evidence and Careful Attention to
Demonstration of Benefit Jeopardizes Its Future

The experimental model of using meticulously evaluated patients as their own
controls, especially when the response to treatment is quantifiable, e.g. color
perfusion, may be the best choice for establishing the benefit of new applications
of HBO. (Seeing is believing)

All Irradiated Brain Tumor Survivors Are At Risk for
Radiation Vascular Injury and Should be
Monitored Carefully and Treated Early With HBOT

HOW EARLY?

